The Minneapolis-based company did not disclose the terms of the financing but said it brings its valuation to $3.75 billion. Reed Jobs and Yosemite joined the round, alongside several new strategic investors.
This financing marks the latest boost for HistoSonics, which had a majority stake acquired by a syndicate of private and public investors for $2.25 billion in August 2025, then closed an oversubscribed $250 million financing in October 2025.
Proceeds are earmarked for continued commercial expansion, clinical development programs, additional regulatory initiatives and further advancement of pipeline applications.
The company’s Edison platform uses focused ultrasound energy — delivered via a robotic arm — to provide histotripsy for the noninvasive destruction of tumors. Edison mechanically destroys and liquifies targeted tissue and tumors without the invasiveness or toxicity of traditional procedures. The platform received its first FDA de novo authorization in the U.S. in 2023. It’s the first and only histotripsy platform cleared for clinical use globally.
Future applications under development include benign prostatic hyperplasia (BPH) treatment and the destruction of kidney tumors.
“Building a generational company requires partners who bring more than capital,” said Mike Blue, chair and CEO, HistoSonics. “This financing continues to add strategic investors who understand our mission, appreciate the magnitude of the opportunity ahead, and share our commitment to delivering lasting value for patients, physicians, and shareholders.”
